Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
37.78
+0.01 (0.03%)
Nov 13, 2024, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 927 employees as of February 15, 2024. The number of employees increased by 131 or 16.46% compared to the previous year.
Employees
927
Change (1Y)
131
Growth (1Y)
16.46%
Revenue / Employee
$866,307
Profits / Employee
-$387,067
Market Cap
5.97B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Feb 15, 2024 | 927 | 131 | 16.46% |
Feb 16, 2023 | 796 | 136 | 20.61% |
Feb 16, 2022 | 660 | -97 | -12.81% |
Feb 18, 2021 | 757 | -60 | -7.34% |
Feb 20, 2020 | 817 | 80 | 10.85% |
Feb 20, 2019 | 737 | 190 | 34.73% |
Feb 20, 2018 | 547 | 112 | 25.75% |
Feb 21, 2017 | 435 | 7 | 1.64% |
Feb 19, 2016 | 428 | 38 | 9.74% |
Feb 17, 2015 | 390 | 86 | 28.29% |
Feb 17, 2014 | 304 | 16 | 5.56% |
Feb 11, 2013 | 288 | 7 | 2.49% |
Feb 13, 2012 | 281 | 11 | 4.07% |
Feb 14, 2011 | 270 | 20 | 8.00% |
Feb 10, 2010 | 250 | -50 | -16.67% |
Feb 10, 2009 | 300 | 0 | - |
Mar 1, 2008 | 300 | 26 | 9.49% |
Mar 5, 2007 | 274 | 16 | 6.20% |
Mar 3, 2006 | 258 | -45 | -14.85% |
Mar 3, 2005 | 303 | -154 | -33.70% |
Mar 3, 2004 | 457 | -66 | -12.62% |
Feb 28, 2003 | 523 | 89 | 20.51% |
Feb 28, 2002 | 434 | 131 | 43.23% |
Jan 31, 2001 | 303 | -49 | -13.92% |
Feb 25, 2000 | 352 | 6 | 1.73% |
Feb 26, 1999 | 346 | 8 | 2.37% |
Feb 27, 1998 | 338 | 51 | 17.77% |
Jan 31, 1997 | 287 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Elanco Animal Health | 9,800 |
Merit Medical Systems | 6,950 |
Stevanato Group | 5,634 |
Inspire Medical Systems | 1,011 |
Lantheus Holdings | 834 |
Blueprint Medicines | 655 |
Cytokinetics | 423 |
IONS News
- 6 days ago - Ionis to present at upcoming investor conferences - PRNewsWire
- 7 days ago - Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - PRNewsWire
- 7 days ago - Ionis reports third quarter 2024 financial results - PRNewsWire
- 9 days ago - Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - PRNewsWire
- 21 days ago - Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling - Seeking Alpha
- 21 days ago - Ionis to hold third quarter 2024 financial results webcast - PRNewsWire
- 23 days ago - WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - PRNewsWire